{
  "slug": "laetrile-cancer-treatment",
  "authoring_model": "Sol 6.1",
  "adversarial_reviewer": "Claude Opus 5.5 (Anthropic)",
  "review_date": "2026-10-14",
  "round": 2,
  "level_before": "Α",
  "level_after": "Α",
  "confidence_before": "Moderate",
  "confidence_after": "Moderate",
  "pmids_checked": 70,
  "pmids_failed": 0,
  "claims_spot_checked": 14,
  "claims_failed": 0,
  "findings_by_severity": {
    "Critical": 0,
    "Major": 0,
    "Minor": 3,
    "Editorial": 0
  },
  "findings": [
    {
      "id": "AR-1",
      "severity": "Minor",
      "type": "rendering",
      "location": "throughout",
      "original": "renderer-dropped spaces and unlabelled bare numeric citations, e.g. 'contradictSC3', 'downgraded fromΒtoΑ', '7033783is nonrandomized', 'pharmacology (7005480;7273266)'",
      "corrected": "'contradict SC3', 'downgraded from Β to Α', 'PMID 7033783 is nonrandomized', 'pharmacology (PMID 7005480; 7273266)' (~96 instances)",
      "evidence": "Known upstream rendering defect; whitespace and PMID label only, no numeric or wording change."
    },
    {
      "id": "AR-2",
      "severity": "Minor",
      "type": "citation_rendering",
      "location": "REFERENCES 2, 7, 9, 20, 21, 25, 26, 27, 30, 32, 38, 39",
      "original": "DOI: .",
      "corrected": "No DOI in PubMed record.",
      "evidence": "PubMed XML for PMID 7005480, 627001, 14281087, 7222669, 448892, 203726, 1060511, 1203898, 1268862, 32122873, 6929726, 26191238 carries no DOI ArticleId."
    },
    {
      "id": "AR-3",
      "severity": "Minor",
      "type": "scoring_text",
      "location": "scorecard final_score.confidence_rationale",
      "original": "density, heterogeneous controls and incomplete access set the confidence, not correctness.",
      "corrected": "evidence density and the near-absence of replicated clinical tests set the confidence, not correctness and not reviewer access depth.",
      "evidence": "hsef-framework.md, Confidence band: 'Confidence reflects evidence density and reproducibility.' Band Moderate re-derived as correct."
    }
  ],
  "rejected_findings": [
    "Headline Alpha argued up to Beta on the six panel-judged 1978 responses: rejected (solicited-success sampling, 26 of 93 records unusable, no counterfactual, cap 2 binds).",
    "Softness of the headline wording versus Moertel's own conclusion: rejected; the refutation is carried by the grade, the safety-subclaim downgrade and the separate Zeta harm model.",
    "Zeta on the rank-1 harm model: independence basis recorded with four distinct failure modes; survives the v5.2 shared-failure test.",
    "Best-supported rival renderer defect: does not fire; models_evaluated[0] is rank 1, is_nominal false, nominal is rank 4.",
    "Momentum 'Mechanistic only' with four named preclinical artifacts.",
    "Divergence 'Contested': reviewer judgement, explicitly disclaimed as not a balanced-evidence claim.",
    "'175 evaluable / one temporary response': already labelled secondary-source verification and listed as a knowledge gap.",
    "Collective-author defect: none.",
    "Rubric-02 cancer hard rules quoted verbatim but declared not triggered; cap-precedence obligation met.",
    "Retracted PMID 23137229 and 34536497 correctly excluded from primary credit (both confirmed Retracted Publication).",
    "Print/e-pub year plus-or-minus 1 differences and PubMed title-case normalisation: rejected per convention."
  ],
  "residual_limitations": [
    "59 of 67 records accessed at abstract/status depth.",
    "The 2019 intravenous dose units and the alginate-chitosan normal-tissue protection conclusion remain unverified against their bodies, as the review states.",
    "provenance_header.generated_by reads 'Codex; HSEF v5.3' rather than naming Sol 6.1 (package-wide field, left for the lead)."
  ],
  "validator": {
    "result": "FAIL",
    "fails": 1,
    "warns": 0,
    "passes": 33,
    "detail": "v5.lay_summary only: shipped validator enforces the v5.4 lay-summary rule against a self-declared v5.3 review. Cross-version artifact.",
    "pre_review_validator": "none present in package"
  },
  "files_changed": [
    "laetrile-cancer-treatment.review.md",
    "laetrile-cancer-treatment.scorecard.json",
    "validator.txt"
  ],
  "consensus_questions": [
    "Has any controlled clinical study of laetrile or amygdalin in cancer patients reported objective tumour response or survival benefit?",
    "Does oral amygdalin or apricot-kernel ingestion produce clinically significant cyanide toxicity at doses used in alternative cancer regimens, and is that activation gut-microbiota dependent?"
  ]
}